Categories AlphaGraphs, Earnings, Health Care
LLY Earnings: Key quarterly highlights from Eli Lilly’s Q2 2023 financial results
Eli Lilly and Company (NYSE: LLY) reported second quarter 2023 earnings results today.
Revenue increased 28% to $8.3 billion compared to the same period a year ago, fueled by volume-driven growth from Mounjaro, Verzenio, Jardiance and Taltz, as well as the sale of rights for Baqsimi.
Reported net income grew 85% to $1.76 billion, or $1.95 per share, compared to last year. Adjusted EPS rose 69% to $2.11.
Both revenue and earnings beat expectations, sending the stock up by 7% in premarket hours on Tuesday.
The company raised its guidance for the full year of 2023. Revenue is now expected to be $33.4-33.9 billion. Reported EPS is expected to be $9.20-9.40 while adjusted EPS is projected to be $9.70-9.90.
Prior performance
Most Popular
CVX Earnings: Chevron reports lower revenue and profit for Q1 2024
Energy exploration company Chevron Corporation (NYSE: CVX) announced first-quarter 2024 financial results, reporting a decline in net profit and revenues. Net income attributable to Chevron Corporation was $5.50 billion or
ABBV Earnings: AbbVie reports lower adj. profit for Q1 2024; revenue edges up
Specialty biopharmaceutical company AbbVie, Inc. (NYSE: ABBV) Friday announced first-quarter 2024 financial results, reporting a decline in adjusted earnings and a modest rise in revenues. The company reported worldwide net
CL Earnings: Key quarterly highlights from Colgate-Palmolive’s Q1 2024 financial results
Colgate-Palmolive Company (NYSE: CL) reported first quarter 2024 earnings results today. Net sales increased 6.2% year-over-year to $5.06 billion. Organic sales increased 9.8%. Net income attributable to Colgate-Palmolive Company was
